{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:00:24Z","timestamp":1791262824465,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1756-8722-7-44","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T01:04:29Z","timestamp":1402535069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors"],"prefix":"10.1186","volume":"7","author":[{"given":"Sven","family":"de Vos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy C","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G","family":"Drachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,12]]},"reference":[{"key":"402_CR1","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005, 23: 8447-8452. 10.1200\/JCO.2005.03.1674.","journal-title":"J Clin Oncol"},{"key":"402_CR2","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006, 24: 3121-3127. 10.1200\/JCO.2005.05.1003.","journal-title":"J Clin Oncol"},{"key":"402_CR3","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008, 26: 4579-4586. 10.1200\/JCO.2007.13.5376.","journal-title":"J Clin Oncol"},{"key":"402_CR4","doi-asserted-by":"crossref","first-page":"Abstract 8509","DOI":"10.1200\/jco.2009.27.15_suppl.8509","volume":"27","author":"C Gisselbrecht","year":"2009","unstructured":"Gisselbrecht C, Glass B, Mounier N, Gill D, Linch D, Trneny M, Bosly A, Shpilberg O, Ketterer N, Moskowitz C, Schmitz N: R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol. 2009, 27: Abstract 8509-","journal-title":"J Clin Oncol"},{"key":"402_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/978-0-387-89520-8_2","volume":"647","author":"CL Law","year":"2009","unstructured":"Law CL, Grewal IS: Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv Exp Med Biol. 2009, 647: 8-36. 10.1007\/978-0-387-89520-8_2.","journal-title":"Adv Exp Med Biol"},{"key":"402_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.cgt.7700527","volume":"10","author":"AW Tong","year":"2003","unstructured":"Tong AW, Stone MJ: Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003, 10: 1-13. 10.1038\/sj.cgt.7700527.","journal-title":"Cancer Gene Ther"},{"key":"402_CR7","doi-asserted-by":"publisher","first-page":"8331","DOI":"10.1158\/0008-5472.CAN-05-0095","volume":"65","author":"CL Law","year":"2005","unstructured":"Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS: Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005, 65: 8331-8338. 10.1158\/0008-5472.CAN-05-0095.","journal-title":"Cancer Res"},{"key":"402_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/08923973.2014.890626","volume":"36","author":"SB Hassan","year":"2014","unstructured":"Hassan SB, Sorensen JF, Olsen BN, Pedersen AE: Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol. 2014, 36: 96-104. 10.3109\/08923973.2014.890626.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"402_CR9","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","volume":"19","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Glennie MJ: Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013, 19: 1035-1043. 10.1158\/1078-0432.CCR-12-2064.","journal-title":"Clin Cancer Res"},{"key":"402_CR10","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","volume":"27","author":"R Advani","year":"2009","unstructured":"Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG: Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent Non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2009, 27: 4371-4377. 10.1200\/JCO.2008.21.3017.","journal-title":"J Clin Oncol"},{"key":"402_CR11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP: Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999, 17: 1244-","journal-title":"J Clin Oncol"},{"key":"402_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004, 103: 275-282. 10.1182\/blood-2003-05-1545.","journal-title":"Blood"},{"key":"402_CR13","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1080\/10428190903128660","volume":"50","author":"WK Weng","year":"2009","unstructured":"Weng WK, Weng WK, Levy R: Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma. 2009, 50: 1494-1500. 10.1080\/10428190903128660.","journal-title":"Leuk Lymphoma"},{"key":"402_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3324\/haematol.2009.008003","volume":"95","author":"M Hussein","year":"2010","unstructured":"Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N: A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010, 95: 845-848. 10.3324\/haematol.2009.008003.","journal-title":"Haematologica"},{"key":"402_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V: Revised response criteria for malignant lymphoma. J Clin Oncol. 2007, 25: 579-586. 10.1200\/JCO.2006.09.2403.","journal-title":"J Clin Oncol"},{"key":"402_CR16","first-page":"120","volume":"41","author":"T Bourcier","year":"2000","unstructured":"Bourcier T, de Saint-Jean M, Brignole F, Goguel A, Baudouin C: Expression of CD40 and CD40 ligand in the human conjunctival epithelium. Invest Ophthalmol Vis Sci. 2000, 41: 120-126.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"402_CR17","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.2001.19.16.3602","volume":"19","author":"F Grange","year":"2001","unstructured":"Grange F, Bekkenk MW, Wechsler J, Meijer CJ, Cerroni L, Bernengo M, Bosq J, Hedelin G, Fink Puches R, van Vloten WA, Joly P, Bagot M, Willemze R: Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol. 2001, 19: 3602-3610.","journal-title":"J Clin Oncol"},{"key":"402_CR18","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ: WHO-EORTC classification for cutaneous lymphomas. Blood. 2005, 105: 3768-3785. 10.1182\/blood-2004-09-3502.","journal-title":"Blood"},{"key":"402_CR19","doi-asserted-by":"publisher","first-page":"74ra22","DOI":"10.1126\/scitranslmed.3001620","volume":"3","author":"B Burington","year":"2011","unstructured":"Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, Stinson S, Stinson J, Januario T, de Vos S, Ansell S, Forero-Torres A, Fedorowicz G, Yang TT, Elkins K, Du C, Mohan S, Yu N, Modrusan Z, Seshagiri S, Yu SF, Pandita A, Koeppen H, French D, Polson AG, Offringa R, Whiting N, Ebens A, Dornan D: CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med. 2011, 3: 74ra22-","journal-title":"Sci Transl Med"},{"key":"402_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1084\/jem.20080238","volume":"205","author":"C Homig-Holzel","year":"2008","unstructured":"Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Muller W, Quintanilla-Martinez L, Gewies A, Ruland J, Rajewsky K, Zimber-Strobl U: Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med. 2008, 205: 1317-1329. 10.1084\/jem.20080238.","journal-title":"J Exp Med"},{"key":"402_CR21","doi-asserted-by":"crossref","first-page":"Abstract 1583","DOI":"10.1182\/blood.V112.11.1583.1583","volume":"112","author":"TS Lewis","year":"2008","unstructured":"Lewis TS, McCormick RS, McEarchern JA, Kissler K, Stone IJ, Gerber H-P, Drachman JG, Grewal I, Law C-L: Preclinical analysis of the combined activity of SGN-40, anti-CD40 monoclonal antibody, with rituximab in Non-Hodgkin lymphoma. Blood. 2008, 112: Abstract 1583-","journal-title":"Blood"},{"key":"402_CR22","doi-asserted-by":"publisher","first-page":"Abstract 2499","DOI":"10.1182\/blood-2006-08-037374","volume":"108","author":"TS Lewis","year":"2006","unstructured":"Lewis TS, Sutherland MSK, Jonas M, Cerveny CG, McCormick R, Wahl AF, Drachman JG, Grewal IS, Law C-L: The humanized anti-CD40 antibody, SGN-40, promotes apoptosis signaling and is effective in combination with standard therapies in lymphoma xenograft models. Blood. 2006, 108: Abstract 2499-10.1182\/blood-2006-08-037374.","journal-title":"Blood"},{"key":"402_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/10428194.2012.710328","volume":"54","author":"A Forero-Torres","year":"2013","unstructured":"Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH: Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2013, 54: 277-283. 10.3109\/10428194.2012.710328.","journal-title":"Leuk Lymphoma"},{"key":"402_CR24","doi-asserted-by":"crossref","first-page":"iv131","DOI":"10.1093\/annonc\/mdr209","volume":"22","author":"L Fayad","year":"2011","unstructured":"Fayad L, Ansell SM, Advani R, Coiffier B, Bartlett N, Stuart R, Forero-Torres A, Kuliczkowski K, Drachman JG: A phase 2B trial comparing dacetuzemab + R-ICE vs placebo + R-ICE in patients with relapsed diffuse large B-cell lymphoma. Ann Oncol. 2011, 22: iv131-iv132.","journal-title":"Ann Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-7-44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T20:54:18Z","timestamp":1649364858000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-7-44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-7-44","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,12]]},"assertion":[{"value":"21 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"44"}}